Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based monoclonal company KaloBios Pharmaceuticals has raised $20 million in the first closing of its series D venture financing.
Subscribe to our email newsletter
The financing was co-led by Mitsubishi UFJ Capital and Genzyme Ventures, both new investors, with the participation of the company’s previous investors, MPM Capital, Alloy Ventures, GBS Ventures, Sofinnova Ventures, Singapore Bioinnovations, 5AM Ventures and Lotus Bioscience Ventures.
Montgomery & Co’s health care team assisted the company with financial aspects of the financing and Gunderson Dettmer provided legal counsel.
David Pritchard, president and CEO of KaloBios, said: “These new funds will enable us to complete our seven Phase I and Phase IIa clinical trials and to prepare to advance our current clinical drug candidates, KB001 and KB003, to Phase IIb clinical trials. They will also allow us to progress a third antibody, KB004, to the investigational new drug stage and to further develop our research pipeline.”